Skip to main content
. 2019 Apr 17;294(22):8732–8744. doi: 10.1074/jbc.RA119.008360

Figure 2.

Figure 2.

Hepatic FXR-mediated cholesterol-lowering effects are blocked by the p-defective Y67F mutation in mice. A and B, FXR-LKO mice were infected with AAV-TBG-GFP or AAV-TBG expressing WT-FXR or Y67F-FXR for 4 weeks (6–7 mice/group). A, cholesterol levels in the plasma, liver, gallbladder, and feces compared with cholesterol levels of control FXR-floxed mice. A horizontal line indicates the mean. B, plasma was subjected to FPLC analysis, and plasma lipoprotein levels were measured in different fractions. C and D, FXR-floxed mice were co-infected with AAV-TBG-Cre and either AAV-TBG-GFP or AAV-TBG expressing WT-FXR or Y67F-FXR for 4 weeks (10 mice/group), and mice were fed a 0.5% CA chow for 6 h, and then plasma and tissue cholesterol levels (C) and plasma lipoprotein levels (D) were measured. Statistical significance was measured using the one-way ANOVA with the Tukey post-test. *, p < 0.05; **, p < 0.01.